Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | CDK4 | P11802 | 5/20 | 0.35 |
| ▸ | CCND1 | P24385 | 5/20 | 0.35 |
| ▸ | CCND2 | P30279 | 5/20 | 0.35 |
| ▸ | CCND3 | P30281 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31532122 | 1.00 | BTK (0.44) | BTKKDM4EALDH1A1GLAGAA | |
| SCHEMBL15781842 | 0.86 | SIK1 (0.39) | BTKKDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL5264435 | 0.86 | FGFR1 (0.37) | BTKKDM4EALDH1A1GLAGAA | |
| SCHEMBL29358283 | 0.84 | BTK (0.37) | BTKCDK4CCND1CCNA2CDK2 | |
| SCHEMBL22190901 | 0.84 | BTK (0.37) | BTKCDK4CCND1CCNA2CDK2 | |
| SCHEMBL22191283 | 0.83 | ALDH1A1 (0.42) | ALDH1A1GLAGAAHPGDMAPK1 | |
| SCHEMBL29352983 | 0.83 | ALDH1A1 (0.42) | ALDH1A1GLAGAAHPGDMAPK1 | |
| SCHEMBL30640299 | 0.83 | PIK3CA (0.40) | BTKCDK4CCND1CCND2CCND3 | |
| SCHEMBL19499676 | 0.82 | CYP1A2 (0.43) | ALDH1A1GAAHPGDMAPK1HSD17B10 | |
| SCHEMBL5061806 | 0.81 | WEE1 (0.39) | BTKHSD17B10FGFR1EGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025043349-A1 | PYRIMIDOPYRIDONE AND PTERIDONE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2025-03-06 | — | — | WO | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044535-A2 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | BTK 1775/4885KDM4E 2139/4885ALDH1A1 1912/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | BTK 1775/4885KDM4E 2139/4885ALDH1A1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.